ReviewOncoTargets and therapy2019

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis.

Marscha S Holleman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.